Literature DB >> 12041912

Dexamethasone enhances vitamin D-24-hydroxylase expression in osteoblastic (UMR-106) and renal (LLC-PK1) cells treated with 1alpha,25-dihydroxyvitamin D3.

Izuru Kurahashi1, Ayako Matsunuma, Tetsuya Kawane, Masatoshi Abe, Noboru Horiuchi.   

Abstract

Chronic glucocorticoid therapy causes rapid bone loss and clinical osteoporosis. We previously found that dexamethasone, a potent glucocorticoid, increased renal expression of vitamin D-24-hydroxylase, which degrades such vitamin D metabolites as 25-hydroxyvitamin D3 and 1alpha,25-dihydroxyvitamin D3 (1,25[OH]2D3). We therefore investigated the mechanisms of this increase in UMR-106 osteoblast-like cells and LLC-PK1 kidney cells. To induce 24-hydroxylase expression, 1,25(OH)2D3 (10(-7)M) and dexamethasone were added simultaneously to the medium of LLC-PK1 cells, and 24 h before dexamethasone treatment, 1,25(OH)2D3 was added to the medium of UMR-106 cells. Dexamethasone dose dependently increased 24-hydroxylase mRNA and enzymatic activity in 1,25(OH)2D3-treated LLC-PK1 and UMR-106 cells. Maximal stimulation was observed with 10(-6) M dexamethasone in both cell lines. The addition of 10(-6) M dexamethasone significantly increased the abundance of 24-hydroxylase mRNA by 24 and 8 h in 1,25(OH)2D3-treated LLC-PK1 and UMR-106 cells, respectively. Stimulation for dexamethasone in UMR-106 cells persisted for up to 48 h. Dexamethasone stimulation of 24-hydroxylase mRNA expression in UMR-106 cells was abolished by pretreatment with cycloheximide, an inhibitor of protein synthesis. Northern and Western analyses indicated that 10(-6) M dexamethasone markedly increased the abundance of c-fos mRNA at 20 min and c-fos protein concentration at 60 min in 1,25(OH)2D3-treated UMR-106 cells but only slightly induced the abundance of c-jun mRNA. The addition of phorbol 12-myristate 13-acetate increased mRNA expression for both c-fos and 24-hydroxylase in 1,25(OH)2D3-treated UMR-106 cells. The effect of dexamethasone on 24-hydroxylase mRNA expression was blocked by RO31-8220, a specific inhibitor of protein kinase C. Thus, dexamethasone in the presence of 1,25(OH)2D3 enhances expression of 24-hydroxylase in UMR-106 osteoblastic cells via new protein synthesis. The mechanism of this effect appears to involve activation of the AP-1 site by increased c-fos protein.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12041912     DOI: 10.1385/ENDO:17:2:109

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  44 in total

1.  Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D.

Authors:  R St-Arnaud; A Arabian; R Travers; F Barletta; M Raval-Pandya; K Chapin; J Depovere; C Mathieu; S Christakos; M B Demay; F H Glorieux
Journal:  Endocrinology       Date:  2000-07       Impact factor: 4.736

2.  Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid. Evidence for a pathway in kidney and bone involving 24-oxidation.

Authors:  G Makin; D Lohnes; V Byford; R Ray; G Jones
Journal:  Biochem J       Date:  1989-08-15       Impact factor: 3.857

3.  Functional assessment of two vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase gene.

Authors:  Y Ohyama; K Ozono; M Uchida; M Yoshimura; T Shinki; T Suda; O Yamamoto
Journal:  J Biol Chem       Date:  1996-11-29       Impact factor: 5.157

4.  Malabsorption of calcium in corticosteroid-induced osteoporosis.

Authors:  H A Morris; A G Need; P D O'Loughlin; M Horowitz; A Bridges; B E Nordin
Journal:  Calcif Tissue Int       Date:  1990-05       Impact factor: 4.333

5.  Stimulation of neonatal mouse calvarial bone resorption by the glucocorticoids hydrocortisone and dexamethasone.

Authors:  H H Conaway; D Grigorie; U H Lerner
Journal:  J Bone Miner Res       Date:  1996-10       Impact factor: 6.741

6.  Hormonal regulation of the osteoblastic phenotype expression in neonatal murine calvarial cells.

Authors:  T L Chen; D Fry
Journal:  Calcif Tissue Int       Date:  1999-04       Impact factor: 4.333

7.  High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton.

Authors:  F Cosman; J Nieves; J Herbert; V Shen; R Lindsay
Journal:  J Bone Miner Res       Date:  1994-07       Impact factor: 6.741

8.  Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells.

Authors:  A M Delany; E Canalis
Journal:  Endocrinology       Date:  1995-11       Impact factor: 4.736

9.  Insulin-like growth factor I suppresses parathyroid hormone (PTH)/PTH-related protein receptor expression via a mitogen-activated protein kinase pathway in UMR-106 osteoblast-like cells.

Authors:  T Kawane; N Horiuchi
Journal:  Endocrinology       Date:  1999-02       Impact factor: 4.736

10.  Regulation of messenger ribonucleic acid expression of 1 alpha,25-dihydroxyvitamin D3-24-hydroxylase in rat osteoblasts.

Authors:  A Nishimura; T Shinki; C H Jin; Y Ohyama; M Noshiro; K Okuda; T Suda
Journal:  Endocrinology       Date:  1994-04       Impact factor: 4.736

View more
  9 in total

1.  Association of glucocorticoid use and low 25-hydroxyvitamin D levels: results from the National Health and Nutrition Examination Survey (NHANES): 2001-2006.

Authors:  Amy L Skversky; Juhi Kumar; Matthew K Abramowitz; Frederick J Kaskel; Michal L Melamed
Journal:  J Clin Endocrinol Metab       Date:  2011-09-28       Impact factor: 5.958

Review 2.  Vitamin D and the kidney.

Authors:  Rajiv Kumar; Peter J Tebben; James R Thompson
Journal:  Arch Biochem Biophys       Date:  2012-03-15       Impact factor: 4.013

3.  Novel mechanism of negative regulation of 1,25-dihydroxyvitamin D3-induced 25-hydroxyvitamin D3 24-hydroxylase (Cyp24a1) Transcription: epigenetic modification involving cross-talk between protein-arginine methyltransferase 5 and the SWI/SNF complex.

Authors:  Tanya Seth-Vollenweider; Sneha Joshi; Puneet Dhawan; Said Sif; Sylvia Christakos
Journal:  J Biol Chem       Date:  2014-10-16       Impact factor: 5.157

4.  Serum 25-hydroxyvitamin D Concentration Significantly Decreases in Patients with COVID-19 Pneumonia during the First 48 Hours after Hospital Admission.

Authors:  Juraj Smaha; Martin Kužma; Peter Jackuliak; Samuel Nachtmann; Filip Max; Elena Tibenská; Neil Binkley; Juraj Payer
Journal:  Nutrients       Date:  2022-06-07       Impact factor: 6.706

5.  Oral Calcidiol Is More Effective Than Cholecalciferol Supplementation to Reach Adequate 25(OH)D Levels in Patients with Autoimmune Diseases Chronically Treated with Low Doses of Glucocorticoids: A "Real-Life" Study.

Authors:  Miguel Ortego-Jurado; José-Luis Callejas-Rubio; Raquel Ríos-Fernández; Juan González-Moreno; Amanda Rocío González Ramírez; Miguel A González-Gay; Norberto Ortego-Centeno
Journal:  J Osteoporos       Date:  2015-06-01

6.  Effect of long term inhaled corticosteroid therapy on adrenal suppression, growth and bone health in children with asthma.

Authors:  Anuradha Kwda; Prematilake Gldc; Batuwita Baui; Kannangoda Kasr; Hewagamage Us; Wijeratne S; Lankatilake Kantha; de Silva Ksh
Journal:  BMC Pediatr       Date:  2019-11-05       Impact factor: 2.125

7.  The Interaction of Vitamin D and Corticosteroids: A Mortality Analysis of 26,508 Veterans Who Tested Positive for SARS-CoV-2.

Authors:  Jimmy T Efird; Ethan J Anderson; Charulata Jindal; Thomas S Redding; Andrew D Thompson; Ashlyn M Press; Julie Upchurch; Christina D Williams; Yuk Ming Choi; Ayako Suzuki
Journal:  Int J Environ Res Public Health       Date:  2021-12-31       Impact factor: 3.390

8.  Free 25-hydroxyvitamin-D concentrations are lower in children with renal transplant compared with chronic kidney disease.

Authors:  Evgenia Preka; Mandy Wan; Karen L Price; David A Long; Helen Aitkenhead; Rukshana Shroff
Journal:  Pediatr Nephrol       Date:  2020-01-22       Impact factor: 3.714

9.  Assessment of Vitamin D Metabolism in Patients with Cushing's Disease in Response to 150,000 IU Cholecalciferol Treatment.

Authors:  Alexandra Povaliaeva; Viktor Bogdanov; Ekaterina Pigarova; Artem Zhukov; Larisa Dzeranova; Zhanna Belaya; Liudmila Rozhinskaya; Galina Mel'nichenko; Natalia Mokrysheva
Journal:  Nutrients       Date:  2021-11-30       Impact factor: 5.717

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.